Sign In
Buy RLFTF
$0.246
+0.0027 (+1.12%)
At Close: Jul 31, 2026
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
05:25pm, Friday, 13'th Dec 2024
Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation GENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF)
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
01:20am, Monday, 11'th Nov 2024
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
01:20am, Monday, 04'th Nov 2024
GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering i
GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
01:20am, Wednesday, 18'th Sep 2024
GENEVA, SWITZERLAND / ACCESSWIRE / September 18, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to deliverin
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
01:20am, Monday, 02'nd Sep 2024
GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
01:25am, Friday, 30'th Aug 2024
RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined ope
Relief Therapeutics Secures up to $11 Million from Royalty Sales
01:20am, Monday, 05'th Aug 2024
Non-dilutive funding to support RLF-TD011 clinical development and pipeline advancement GENEVA, SWITZERLAND / ACCESSWIRE / August 5, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
07:00am, Thursday, 27'th Jun 2024
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to de
Relief Therapeutics Announces Executive Changes
01:20am, Monday, 03'rd Jun 2024
GENEVA, SWITZERLAND / ACCESSWIRE / June 3, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to del
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innova
Relief Therapeutics has Published its Annual Report
01:20am, Tuesday, 30'th Apr 2024
GENEVA, SWITZARLAND / ACCESSWIRE / April 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatmen
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
11:45am, Friday, 26'th Apr 2024
Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESSWIRE / April 26, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF, RLFTY) (Relief Therapeutics, or the C
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
02:20am, Wednesday, 27'th Mar 2024
Relief Therapeutics Calls Extraordinary General Meeting Anticipated Board of Directors Overhaul GENEVA, SWITZERLAND / ACCESSWIRE / March 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
01:00am, Wednesday, 28'th Feb 2024
3-year CHF 50 million capital commitment from GEM Relief advances strategic transformation GENEVA, SWITZERLAND / ACCESSWIRE / February 28, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(
